Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00096967
Status:
COMPLETED
Last Update Posted:
2014-03-26
First Post:
2004-11-17
Brief Title:
A Study to Evaluate Avastin in Patients Treated in a Previous Genentech-Sponsored Cancer Study
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
An Open-Label Multicenter Extension Study of rhuMAb VEGF Bevacizumab in Subjects Treated in a Previous Genentech-Sponsored Cancer Study
Status:
COMPLETED
Status Verified Date:
2014-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open-label extension study Subjects who have received rhuMAb VEGF therapy in Study AVF2107g AVF2119g or AVF2192g and who completed the parent study are eligible for inclusion in this trial Subjects who have received placebo in Study AVF2107g or AVF2192g are also eligible
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None